Cardiac amyloidosis in Latin America: Gaps and opportunities to increase awareness of the disease. Findings from the AMILO-LATAM research group
- 31.05.2022
- International Corner
Erschienen in:
- Verfasst von
- Fernando Mut, MD, FASNC
- Isabel Carvajal, MD
- Jorge Camilletti, MD, PhD, FACC
- Juan Erriest, MD, PhD
- Erick Alexanderson, MD, FACC, FESC
- Gabriel Blacher Grossman, MD, PhD, FASNC
- Erschienen in
- Journal of Nuclear Cardiology | Ausgabe 4/2023
Abstract
Background
Cardiac amyloidosis (CA) is an under-diagnosed disease presenting as a restrictive cardiomyopathy with high morbidity and mortality. Wild-type transthyretin amyloid cardiomyopathy (ATTR-CM) is mostly seen in elderly patients, with increasing prevalence as life expectancy is growing. New diagnostic imaging techniques and treatments allow for a better prognosis, but lack of clinical awareness delays timely diagnosis and appropriate management. Our purpose was to investigate the knowledge of clinicians regarding ATTR-CM and to assess the availability of imaging resources in the Latin-American region.
Methods and Results
Two online surveys were distributed among clinicians and nuclear medicine professionals, respectively: one asking about awareness of CA in different clinical scenarios, and the other about the availability of diagnostic resources and studies performed. 406 responses were received for the first survey and 82 for the second, representing 17 and 14 countries, respectively. A significant lack of awareness was identified among clinicians, although appropriate diagnostic resources are generally available. Survey data showed that very few patients are evaluated for ATTR-CM in most Latin-American countries.
Conclusions
The surveys demonstrated the need for educational programs and other measures to increase clinical awareness and early detection of CA, so patients receive timely treatment and management of the disease.
Anzeige
- Titel
- Cardiac amyloidosis in Latin America: Gaps and opportunities to increase awareness of the disease. Findings from the AMILO-LATAM research group
- Verfasst von
-
Fernando Mut, MD, FASNC
Isabel Carvajal, MD
Jorge Camilletti, MD, PhD, FACC
Juan Erriest, MD, PhD
Erick Alexanderson, MD, FACC, FESC
Gabriel Blacher Grossman, MD, PhD, FASNC
- Publikationsdatum
- 31.05.2022
- Verlag
- Springer International Publishing
- Erschienen in
-
Journal of Nuclear Cardiology / Ausgabe 4/2023
Print ISSN: 1071-3581
Elektronische ISSN: 1532-6551 - DOI
- https://doi.org/10.1007/s12350-022-03005-5
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.
